Immunocore Holdings plc, a biopharmaceutical company based in the United Kingdom, released a Form 8-K filing on January 10, 2025. In the filing, the company reported a preliminary estimate of its cash and cash equivalents as of December 31, 2024. According to the report, Immunocore estimates its cash and cash equivalents to be approximately $820 […]